This clinical trial is focused on studying a type of cancer called Relapsed/Refractory Follicular Lymphoma. This is a condition where the cancer has returned or is not responding to treatment. The study is comparing a new treatment called axicabtagene ciloleucel with the standard treatments that are currently used for this type of lymphoma. Axicabtagene ciloleucel is a type of cell therapy, which means it uses specially modified cells to help fight the cancer. The standard treatments being compared include medications like Vincristine Sulfate, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisolone, Rituximab, and Bendamustine Hydrochloride.

The purpose of the study is to see if axicabtagene ciloleucel is more effective than the standard treatments in helping patients live longer without the cancer getting worse. Participants in the study will receive either the new treatment or one of the standard treatments. The study will monitor the progress of the disease and any side effects that may occur. The treatment will be given through an infusion, which means it is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. The study aims to provide valuable information on whether axicabtagene ciloleucel can offer a better outcome for patients with relapsed or refractory follicular lymphoma compared to the current standard treatments. This research is important for developing new and improved ways to treat this type of cancer.